Related Experiment Video
Updated: Mar 2, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Minimal access surgery for mitral valve endocarditis
Cristina Barbero1, Giovanni Marchetto1, Davide Ricci1
1Department of Cardiovascular and Thoracic Surgery, University of Torino, Città della Salute e della Scienza-San Giovanni Battista Hospital 'Molinette', Torino, Italy.
Objectives:
Minimal access mitral valve surgery (MVS) has already proved to be feasible and effective with low perioperative mortality and excellent long-term outcomes. However, experience in more complex valve diseases such as infective endocarditis (IE) still remains limited. The aim of this retrospective study was to evaluate early and long-term results of minimal access MVS for IE.
Methods:
Data were entered into a dedicated database. Analysis was performed retrospectively for the 8-year period between January 2007 and April 2015.
Results:
During the study period, 35 consecutive patients underwent minimal access MVS for IE at our department. Twenty-four had diagnosis of native MV endocarditis (68.6%) and 11 of mitral prosthesis endocarditis (31.4%).Thirty patients underwent early MVS (85.7%), and 5 patients were operated after the completion of antibiotic treatment (14.3%). Seven patients underwent MV repair (20%), 17 patients underwent MV replacement (48.6%), and 11 patients underwent mitral prosthesis replacement (31.4%). Thirty-day mortality was 11.4% (4 patients). No neurological or vascular complications were reported. One patient underwent reoperation for prosthesis IE relapse after 37 days. Overall actuarial survival rate at 1 and 5 years was 83%; freedom from MV reoperation and/or recurrence of IE at 1 and 5 years was 97%.
Conclusions:
Minimally invasive MVS for IE is feasible and associated with good early and long-term results. Preoperative accurate patient selection and transoesophageal echocardiography evaluation is mandatory for surgical planning.
Insights
Minimal access mitral valve surgery (MVS) is effective for infective endocarditis (IE), showing good early and long-term outcomes. Careful patient selection and echocardiography are crucial for successful minimally invasive MVS in IE cases.
Area of Science:
- Cardiovascular Surgery
- Infective Diseases
- Minimally Invasive Procedures
Background:
- Minimal access mitral valve surgery (MVS) is established as safe and effective.
- Limited data exists for MVS in complex cases like infective endocarditis (IE).
Purpose of the Study:
- To evaluate the early and long-term results of minimally invasive MVS for patients with infective endocarditis.
Main Methods:
- Retrospective analysis of 35 consecutive patients undergoing minimally invasive MVS for IE between January 2007 and April 2015.
- Included native valve endocarditis and prosthesis endocarditis cases.
- Surgical procedures involved mitral valve repair or replacement.
Main Results:
- 30-day mortality was 11.4%.
- Actuarial survival at 1 and 5 years was 83%.
- Freedom from reoperation or IE recurrence at 1 and 5 years was 97%.
Conclusions:
- Minimally invasive MVS for IE is feasible and yields favorable early and long-term outcomes.
- Accurate preoperative patient selection and transesophageal echocardiography are essential for surgical planning.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Endocarditis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Stenosis I: Introduction
Mitral Stenosis IV: Nursing Management

